Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 631-638

  Mecocci, Patrizia ^a   Polidori, Maria Cristina ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Alzheimer's disease; Antioxidant; Clinical trial; Free radical; Mild cognitive impairment; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; ASCORBIC ACID; CURCUMIN; DONEPEZIL; EPIGALLOCATECHIN GALLATE; FLAVONOID; IDEBENONE; ISOPROSTANE; MEMANTINE; PLACEBO; PRAMIPEXOLE; RESVERATROL; SELENIUM; THIOCTIC ACID; UBIQUINONE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; COGNITION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; FOLLOW UP; GINKGO BILOBA; HUMAN; LIPID PEROXIDATION; MILD COGNITIVE IMPAIRMENT; MORTALITY; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ALZHEIMER DISEASE; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HUMANS;

EID: 84858148877     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.10.006     Document Type: Review

References (94)

1. World Alzheimer Report Alzheimer's Disease International http://www.alz.co.uk/research/world-report.
2. De la Torre J.C. Alzheimer's disease: how does it start?. J. Alzheimers Dis. 2002, 4:497-512.
3. Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., Luchsinger J.A., Ogunniyi A., Perry E.K. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008, 7:812-826.
4. Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010, 9:702-716.
5. Sies H. Oxidative stress: introductory remarks. Oxidative Stress 1985, Academic Press, Orlando. H. Sies (Ed.).
6. Mariani E., Polidori M.C., Cherubini A., Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 827:65-75.
7. Mangialasche F., Polidori M.C., Monastero R., Ercolani S., Camarda C., Cecchetti R., Mecocci P. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res. Rev. 2009, 8:285-305.
8. Sies H. Strategies of antioxidant defense. Eur. J. Biochem. 1993, 215:213-219.
9. Middleton L.E., Yaffe K. Promising strategies for the prevention of dementia. Arch. Neurol. 2009, 66:1210-1215.
10. Mecocci P., Mariani E., Cornacchiola V., Polidori M.C. Antioxidants for the treatment of mild cognitive impairment. Neurol. Res. 2004, 26:598-602.
11. Pratico' D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann. N. Y. Acad. Sci. 2008, 1147:70-78.
12. Stocker R. Vitamin E. Novartis Found. Symp. 2007, 282:77-87.
13. Aggarwal B.B., Sundaram C., Prasad S., Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem. Pharmacol. 2010, 8:1613-1631.
14. Polidori M.C., Stahl W., Sies H., Brigelius-Flohe R. Vitamin E, metabolism and biological activity of metabolic products. The Encyclopedia of Vitamin E 2007, 11-20. New York, CAB International. V. Preedy, R. Watson (Eds.).
15. Pratico' D., Polidori M.C., Mecocci P. Vitamin E, Dementia, and Cognitive Function. Vitamins in the Prevention of Human Diseases 2010, Walter de Gruyter. H. Wolfgang, O. Rima (Eds.).
16. Iuliano L., Monticolo R., Straface G., Spoletini I., Gianni W., Caltagirone C., Bossu' P., Spalletta G. Vitamin E and enzymatic/oxidative stress-driven oxysterols in amnestic mild cognitive impairment subtypes and Alzheimer's disease. J. Alzheimers Dis. 2010, 21:1383-1392.
17. Sung S., Yao Y., Uryu K., Yang H., Lee V.M., Trojanowski J.Q., Pratico' D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004, 18:323-325.
18. Pratico' D., Clark C.M., Liun F., Rokach J., Lee V.Y., Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch. Neurol. 2002, 59:972-976.
19. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., Breitner J.C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 2004, 61:82-88.
20. Luchsinger J.A., Wang M.X., Shea S., Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch. Neurol. 2003, 60:203-208.
21. Yaffe K., Clemons T.E., McBee W.L., Lindblad A.S. Impact of antioxidants, zinc and copper on cognition in the elderly: a randomized, controlled trial. Neurology 2004, 63:1705-1707.
22. Dumont M., Lin M.T., Beal M.F. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J. Alzheimers Dis. 2010, 20:S633-S643.
23. Morris M.C., Beckett L.A., Scherr P.A., Hebert L.E., Bennett D.A., Field T.S., Evans D.A. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1998, 12:121-126.
24. Masaki K.H., Losonczy K.G., Izmirlian G., Foley D.J., Ross G.W., Petrovitch H., Havlik R., White L.R. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000, 54:1265-1272.
25. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Wilson R.S. Vitamin E and cognitive decline in older persons. Arch. Neurol. 2002, 59:1125-1132.
26. Grodstein F., Chen J., Willett W.C. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am. J. Clin. Nutr. 2003, 77:975-984.
27. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., Breteler M.M. Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA 2002, 287:3223-3229.
28. Boothby L.A., Doering P.L. Vitamin C and vitamin E for Alzheimer's disease. Ann. Pharmacother. 2005, 39:2073-2080.
29. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 1997, 336:1216-1222.
30. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352:2379-2388.
31. Brewer G.J. Why vitamin E therapy fails for treatment of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:27-30.
32. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142:37-46.
33. Roberts L.J., Oates J.A., Linton M.F., Fazio S., Meador B.P., Gross M.D., Shyr Y., Morrow J.D. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic. Biol. Med. 2007, 43:1388-1393.
34. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta analysis. JAMA 2007, 297:842-857.
35. Williamson K.S., Gabbita S.P., Mou S., West M., Pye Q.N., Markesbery W.R., Coney R.V., Grammas P., Reimann-Philipp U., Floyd R.A., Hensley K. The nistration product 5-nitro-gamma-tocopherol is increate in the Alzheimer brain. Nitric Oxide 2002, 6:221-227.
36. Spencer J.P. Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain. Proc. Nutr. Soc. 2010, 69:244-260.
37. 2. J. Agric. Food Chem. 2000, 48:979-981.
38. Srividhya R., Jyothilakshmi V., Arulmathi K., Senthilkumaran V., Kalaiselvi P. Attenuation of senescence-induced oxidative exacerbations in aged rat brain by (-)-epigallocatechin-3-gallate. Int. J. Dev. Neurosci. 2008, 26:217-223.
39. Lotito S.B., Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?. Free Radic. Biol. Med. 2006, 41:1727-1746.
40. Laurin D., Masaki K.H., Foley D.J., White L.R., Launer L.J. Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. Am. J. Epidemiol. 2004, 159:959-967.
41. Commenges D., Scotet V., Renaud S., Jacqmin-Gadda H., Barberger-Gateau P., Dartigues J.F. Intake of flavonoids and risk of dementia. Eur. J. Epidemiol. 2000, 16:357-363.
42. Letenneur L., Proust-Lima C., Le Gouge A., Dartigues J.F., Barberger-Gateau P. Flavonoid intake and cognitive decline over a 10-year period. Am. J. Epidemiol. 2007, 165:1364-1371.
43. Williams R.J., Spencer J.P., Rice-Evans C. Flavonoids: antioxidants or signaling molecules?. Free Radic. Biol. Med. 2004, 36:838-849.
44. Dai Q., Borenstein A.R., Wu Y., Jackson J.C., Larson E.B. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am. J. Med. 2006, 119:751-759.
45. Ho R.C., Cheung M.W., Fu E., Win H.H., Zaw M.H., Ng A., Mak A. Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. Am. J. Geriatr. Psychiatry 2011, 19:607-617.
46. Morillas-Ruiz J.M., Rubio-Perez J.M., Albaladejo M.D., Zafrilla P., Parra S., Vidal-Guevara M.L. Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients. J. Neurol. Sci. 2010, 299:175-178.
47. Das D.K., Mukherjee S., Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail. Rev. 2010, 15:467-477.
48. Kennedy D.O., Wightman E.L., Reay J.L., Lietz G., Okello E.J., Wilde A., Haskell C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91:1590-1597.
49. Hatcher H., Planalp R., Cho J., Torti F.M., Torti S.V. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 2008, 65:1631-1652.
50. Ono K., Hasegawa K., Yoshiike Y., Takashima A., Yamada M., Naiki H. Nordihydroguaiaretic acid potently breaks down preformed Alzheimer's β-amyloid fibrils in vitro. J. Neurochem. 2002, 81:434-440.
51. Hamaguchi T., Ono K., Yamada M. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell. Mol. Life Sci. 2006, 1-15.
52. Hamaguchi T., Ono K., Yamada M. Curcumin and Alzheimer's disease. CNS Neurosci. Ther. 2010, 16:285-297.
53. Baum L., Lam C.W., Cheung S.K., Kwok T., Lui V., Tsoh J., Lam L., Leung V., Hui E., Ng C., Woo J., Chiu H.F., Goggins W.B., Zee B.C., Cheng K.F., Fong C.Y., Wong A., Mok H., Chow M.S., Ho P.C., Ip S.P., Ho C.S., Yu X.W., Lai C.Y., Chan M.H., Szeto S., Chan I.H., Mok V. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer's disease. J. Clin. Psychopharmacol. 2008, 28:110-113.
54. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res. 2005, 2:131-136.
55. Ringman J.M., Cole G.M., Tend E. Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study. Proceedings of the International Conference of Alzheimer's disease 2008, Chicago, abstract.
56. Le W.D., Jankovic J., Xie W., Appel S.H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J. Neural Transm. 2000, 107:1165-1173.
57. Zhang S., Hedskog L., Petersen C.A., Winblad B., Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J. Alzheimers Dis. 2010, 21:389-402.
58. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1998, 1366:211-223.
59. Su B., Wang X., Bonda D., Perry G., Smith M., Zhu X. Abnormal mitochondrial dynamics - a novel therapeutic target for Alzheimer's disease?. Mol. Neurobiol. 2010, 41:87-96.
60. Jones R.W. Dimebon disappointment. Alzheimers Res. Ther. 2010, 2:25.
61. Mancuso M., Orsucci D., Volpi L., Calsolaro V., Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr. Drug Targets 2010, 11:111-121.
62. James A.M., Sharpley M.S., Manas A.R., Frerman F.E., Hirst J., Smith R.A., Murphy M.P. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem. 2007, 282:14708-14718.
63. Bentinger M., Tekle M., Dallner G. Coenzyme Q - biosynthesis and functions. Biochem. Biophys. Res. Commun. 2010, 396:74-79.
64. Maczurek A., Hager K., Kenklies M., Sharman M., Martins R., Engel J., Carlson D.A., Munch G. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv. Drug Deliv. Rev. 2008, 60:1463-1470.
65. Hager K., Marahrens A., Kenklies M., Riederer P., Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch. Gerontol. Geriatr. 2001, 32:275-282.
66. Hager K., Kenklies M., McAfoose J., Engel J., Munch G.G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J. Neural Transm. Suppl. 2007, 72:189-193.
67. Chaturvedi R.K., Beal M.F. Mitochondrial approach for neuroprotection. Ann. N. Y. Acad. Sci. 2008, 1147:395-412.
68. Senin U., Parnetti L., Barbagallo-Sangiorgi G., Bartorelli L., Bocola V., Capurso A., Cuzzupoli M., Denaro M., Marigliano V., Tammaro A.E., Fioravanti M. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch. Gerontol. Geriatr. 1992, 15:249-260.
69. Bergamasco B., Scarzella L., La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of Alzheimer type. Funct. Neurol. 1994, 9:161-168.
70. Gutzmann H., Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a two-year double-blind multicentre study. J. Neural Transm. Suppl. 1998, 54:301-310.
71. Weyer G., Babej-Dölle R.M., Hadler D., Hoffmann S., Hermann W.M. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997, 36:73-82.
72. Thal L.J., Grundman M., Berg J., Ernstrom K., Margolin R., Pfeiffer E., Weiner M.F.F., Zamrini E., Thomas R.G. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003, 61:1498-1502.
73. Abad M.J., Bedoya L.M., Bermejo P. An update on drug interactions with the herbal medicine Ginkgo biloba. Curr. Drug Metab. 2010, 11:171-181.
74. Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009, 1:CD003120.
75. De Kosky S.T., Fitzpatrick A., Ives D.G., Saxton J., Williamson J., Lopez O.L., Burke G., Fried L., Kuller L.H., Robbins J., Tracey R., Woolard N., Dunn L., Kronmal R., Nahin R., Furberg C. GEMS Investigators, The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp. Clin. Trials 2006, 27:238-253.
76. Snitz B.E., O'Meara E.S., Carlson M.C., Arnold A.M., Ives D.G., Rapp S.R., Saxton J., Lopez O.L., Dunn L.O., Sink K.M., DeKosky S.T. Ginkgo Evaluation of Memory (GEM) Study Investigators, Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009, 302:2663-2670.
77. Andrieu S., Ousset P.J., Coley N., Ouzid M., Mathiex-Fortunet H., Vellas B. GuidAge study: a 5-year double-blind, randomized trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Curr. Alzheimer Res. 2008, 5:406-415. the GuidAge study Group.
78. Parasassi T., Brunelli R., Costa G., De Spirito M., Krasnowska E., Lundeberg T., Pittaluga E., Ursini F. Thiol redox transitions in cell signaling: a lesson from N-acetylcysteine. Sci. World J. 2010, 10:1192-1202.
79. Pocernich C.B., Bader Lange M.L., Sultana R., Butterfield D.A. Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:452-469.
80. Liu G., Men P., Perry G., Smith M.A. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol. Biol. 2010, 610:123-144.
81. Breteler M.M., Bots M.L., Ott A., Hofman A. Risk factors for vascular disease and dementia. Haemostasis 1998, 28:167-173.
82. Breteler M.M. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann. N.Y. Acad. Sci. 2000, 903:457-465.
83. Vagnucci A.H., Li W.W. Alzheimer's disease and angiogenesis. Lancet 2003, 361:605-608.
84. De la Torre J.C. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol. Aging 2000, 21:331-342.
85. Aliev G., Smith M.A., de la Torre J.C., Perry G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 2004, 4:649-663.
86. Aliev G. Is non-genetic Alzheimer's disease a vascular disorder with neurodegenerative consequences?. J. Alzheimers Dis. 2002, 4:513-516.
87. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010, 120:287-296.
88. Polidori M.C. Oxidative stress and risk factors of Alzheimer's disease: clues to prevention and therapy. J. Alzheimers Dis. 2004, 6:185-191.
89. Albert M.S., Dekosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
90. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.W., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
91. Macready L., Butler L.T., Kennedy O.B., Ellis J.A., Williams C.M., Spencer J.P. Cognitive tests used in chronic adult human randomised controlled trial micronutrient and phytochemical intervention studies. Nutr. Res. Rev. 2010, 23:200-229.
92. Viswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia. How to move forward?. Neurology 2009, 72:368-374.
93. Barnes D.E., Yaffe K. Predicting dementia: role of dementia risk indices. Future Neurol. 2009, 4:555-560.
94. De la Torre J.C. Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res. Rev. 2010, 9:218-225.